Delisting risk
AEON Biopharma
Develops a therapeutic Botox biosimilar candidate for broad-label use.
$0.3031
After-hours close−0.01 (−1.85%)
At close$0.3088(+5.07%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.07 | — | — |
| Aug 2026 | −$0.23 | −$0.02 | +91.1% |
| Aug 2026 | −$0.23 | −$0.02 | +91.1% |
| May 2026 | −$0.44 | −$0.44 | 0.0% |
| Mar 2026 | −$0.21 | −$3.72 | −1,714.6% |
The latest year is open to everyone — the 12 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | −$0.07 | — | — | — | — | — |
| Aug 12, 2026 | −$0.23 | −$0.02 | +91.1% | — | — | — |
| Aug 11, 2026 | −$0.23 | −$0.02 | +91.1% | — | — | — |
| May 14, 2026 | −$0.44 | −$0.44 | 0.0% | — | — | — |
| Mar 30, 2026 | −$0.21 | −$3.72 | −1,714.6% | — | — | — |
The latest year is open to everyone — the 12 quarters behind it read with an account. Sign in | ||||||
| Nov 14, 2025 | ||||||
| Aug 12, 2025 | ||||||
| May 14, 2025 | ||||||
| Mar 24, 2025 | ||||||
| Nov 13, 2024 | ||||||
| Aug 12, 2024 | ||||||
| May 14, 2024 | ||||||
| Mar 29, 2024 | ||||||
| Jun 30, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Dec 31, 2022 | ||||||
| Sep 30, 2022 | ||||||